Drug intelligence / Profile preview

AST-Fp-13

Development stage: Preclinical
Lead developer: ASTRA Therapeutics
Modality: Small Molecules

Overview

AST-Fp-13 is a novel, species-specific parasiticide (Parabulin) being developed by ASTRA Therapeutics for the treatment of protozoan infections in farm animals, such as coccidiosis. Generated using the company's proprietary ParaX platform, AST-Fp-13 is designed to selectively target and disrupt parasite tubulin (microtubules), thereby inhibiting cell division in the parasite while sparing the host animal. The drug is currently in the Proof of Concept (PoC) stage of development.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on AST-Fp-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-Fp-13.

Explore the full profile